DIMA KUZMIN

Dima Kuzmin stands as a prominent figure in the biotechnology investment landscape, serving as a Managing Partner at 4BIO Capital. This specialist venture capital firm is renowned for its dedicated focus on advanced therapies, including gene therapy, cell therapy, RNA therapy, oligonucleotide therapy, and gene editing. At 4BIO Capital, Dima Kuzmin is instrumental in leading investment strategies, identifying pioneering companies, and driving the growth of transformative healthcare solutions.

His role at 4BIO Capital involves overseeing all aspects of the investment lifecycle, from initial deal sourcing and due diligence to portfolio management and strategic exits. Dima's deep understanding of both scientific innovation and financial markets enables him to pinpoint companies with the potential to revolutionize medicine and deliver significant returns. He is particularly keen on early-stage and growth-stage companies that are developing disruptive platforms and therapies addressing critical unmet medical needs across various disease areas.

Before co-founding 4BIO Capital, Dima Kuzmin built a robust career in investment banking, specializing in the healthcare sector. He held significant positions at leading global financial institutions such as UBS and Credit Suisse. During his tenure in investment banking, Dima gained extensive experience in mergers and acquisitions (M&A), capital markets transactions, and strategic advisory for pharmaceutical and biotechnology companies. This background provided him with invaluable insights into the financial intricacies and strategic imperatives of the life sciences industry, which he now leverages to guide 4BIO Capital's investment decisions.

While specific individual investments are often part of 4BIO Capital's broader portfolio, Dima Kuzmin has been central to the firm's strategy of backing companies that are at the forefront of advanced therapy development. These investments typically target firms developing novel therapeutic modalities for rare diseases, oncology, and other areas where conventional treatments fall short. His leadership contributes to 4BIO Capital's reputation for supporting companies that not only promise strong financial returns but also hold the potential for profound patient impact.

Through his work, Dima Kuzmin continues to shape the future of medicine by fostering innovation and providing crucial capital to the next generation of biotech leaders. His blend of scientific acumen and financial expertise makes him a key driver in advancing the field of advanced therapies and bringing life-changing treatments to patients worldwide.